News Non-Clinical Safety Considerations when Developing Targeted Protein Degraders 5/10/22 Read more Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine 4/25/22 Read more Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics 4/25/22 Read more KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI) 4/7/22 Read more Undruggable Leaders Forum, September 15-16, 2021 9/15/21 Read more The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation 7/6/21 Read more Marking Kymera’s 5-Year Anniversary 6/7/21 Read more Ligase Targeting Drug Development Summit, May 25 – 27, 2021 5/26/21 Read more Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021 2/16/21 Read more 2nd Annual North American Protein Degradation Congress, February 16-24, 2021 2/16/21 Read more
